Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4486 |
Name | malignant biphasic mesothelioma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer cell type cancer malignant mesothelioma malignant biphasic mesothelioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02798536 | Phase I | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma | Completed | USA | 0 |
NCT03436732 | Phase I | LMB-100 + SVP-rapa | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | Terminated | USA | 0 |
NCT06155279 | Phase II | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab | Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA) | Recruiting | ITA | 0 |
NCT06790706 | Phase II | AB154 + Zimberelimab AB154 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers (IMMUNORARE5) | Not yet recruiting | FRA | 0 |
NCT06885697 | Phase I | Cyclophosphamide + Fludarabine TNhYP218 CAR-T cells | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | Not yet recruiting | USA | 0 |